Enzyme immunoassay for the quantitative determination of Bevacizumab (Avastin®) in serum and plasma.
The Matriks Biotek Shikari® Q-BEVA Enzyme Immunoassay has been developed for the quantitative analysis of biologically active form of free bevacizumab®(Avastin®)* in serum and plasma samples.
Serum through levels might be related to predict some clinical outcome during maintenance therapy. It was also possible that the surveillance of circulating concentration during maintenance therapy represents a direct and/or indirect factor for some other side effects. In this context, identification of biomarkers for (non-) response and risk factors for adverse drug reactions that might be related to serum drug levels and maintaining the effective minimum concentration in order to potentially avoid some side effects with a reliable method might be beneficial.
中文版
English
